Afatinib Completed Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

CompletedTreatment2 IdentifierTitleDrugs
NCT01415011Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients
NCT02597946Afatinib in NSCLC With HER2 Mutation
NCT00525148LUX Lung 2 Phase II Single Arm BIBW 2992 Afatinib in NSCLC With EGFR Activating Mutations
NCT00730925Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
NCT00796549BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
NCT01003899A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]
NCT02747953Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib
NCT02369484Afatinib in NSCLC With HER2 Mutation